Plegridy Observational Program

The primary objectives of the study are to determine the incidence of serious adverse events
(SAEs) in participants with relapsing forms of multiple sclerosis (MS) in routine clinical
practice and to assess the overall long-term clinical effectiveness of Plegridy in
participants with relapsing forms of MS in routine clinical practice. The secondary
objectives of this study in this study population are to describe Plegridy prescription and
utilization adherence patterns in routine clinical practice; to assess the specific long-term
clinical effectiveness of Plegridy in participants with relapsing forms of MS in routine
clinical practice; to monitor the safety and tolerability of Plegridy in routine clinical
practice by assessing the incidence of adverse events (AEs) of flu-like symptoms (FLS),
injection site reactions (ISRs), and AEs (including laboratory abnormalities) leading to
treatment discontinuation; to assess the effect of FLS on participant-reported effectiveness
of, and satisfaction with, prophylactic management using a FLS-Visual Analog Scale (FLS-VAS);
to evaluate the change in health-related quality of life (HRQoL), FLS, FLS-VAS, healthcare
resource consumption, and treatment adherence over time.